Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Whole Transcriptome Analysis (Rna-Seq) By Next-Generation Sequencing Of PI4KA-LCLs

ABSTRACT: Whole Transcriptome Analysis (Rna-Seq) By Next-Generation Sequencing Of PI4KA-LCLs

PROVIDER: PRJEB72024 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR12522419_1.fastq.gz	Fastqsanger.gz
	ERR12522419_2.fastq.gz	Fastqsanger.gz
	ERR12522420_1.fastq.gz	Fastqsanger.gz
	ERR12522420_2.fastq.gz	Fastqsanger.gz
	ERR12522421_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 56

Similar Datasets

Whole Transcriptome Analysis (Rna-Seq) By Next-Generation Sequencing Of PI4KA-LCLs

Project description:We performed transcriptome analysis to decipher the role of PI4KA in B cell physiology.

2025-01-31 | E-MTAB-13729 | biostudies-arrayexpress

Whole Transcriptome Analysis (Rna-Seq) By Next-Generation Sequencing of Rubinstein-Taybi syndrome (RSTS) Lymphoblastoid Cell Lines (LCLs)

Project description:Whole Transcriptome Analysis (Rna-Seq) By Next-Generation Sequencing of Rubinstein-Taybi syndrome (RSTS) Lymphoblastoid Cell Lines (LCLs)

| PRJEB75397 | ENA

Next generation sequence analysis

Project description:Next generation sequence analysis

| PRJNA560769 | ENA

HDX-MS analysis of PI4Ka trimer and FAM126a (415-521) with calcineurin

Project description:We used HDX-MS to map novel binding sites of calcineurin on PI4KA and FAM126A. Calcineurin binds to PxIxIT and LxVP motifs on PI4KA and FAM126A indicating a novel regulatory mechanism of Pi4KA by calcineurin

2024-09-03 | PXD050633 | Pride

Next Generation Sequencing of OVA-treated MutuDC Transcriptome

Project description:Next Generation Sequencing of OVA-treated MutuDC Transcriptome

| PRJNA1214793 | ENA

HDX-MS analysis of a TTC7B specific nanobody to inhibit EFR3 mediated PI4KA recruitment

Project description:Phosphatidylinositol 4 kinase III (PI4KIII/PI4KA) is an essential lipid kinase that is critical for regulating plasma membrane identity. PI4KA is primarily recruited to the plasma membrane through targeted recruitment by the proteins EFR3A and EFR3B, with these binding to the PI4KA accessory proteins TTC7 (TTC7A and TTC7B) and FAM126 (FAM126A and FAM126B). Here we characterised how both EFR3 isoforms interact with all possible TTC7 and FAM126 combinations and developed a nanobody that specifically blocks EFR3 mediated PI4KA recruitment in TTC7B containing complexes. Using a yeast display approach, we generated a nanobody that is selective for TTC7B and blocks EFR3 binding. Cryo-electron microscopy and hydrogen deuterium exchange mass spectrometry reveal that the nanobody sterically blocks EFR3 recruitment and shows an extended interface with both PI4KA and TTC7B. Overall, this work provides insight into PI4KA regulation and is a useful tool for manipulating unique complexes of PI4KA that may be valuable for future therapeutic targeting of PI4KA.

2025-11-20 | PXD066213 | Pride

Whole Transcriptome Analysis (Rna-Seq) By Next-Generation Sequencing of hAF-EVs

Project description:Whole Transcriptome Analysis (Rna-Seq) By Next-Generation Sequencing of hAF-EVs

| PRJEB75242 | ENA

Defining the molecular mechanism of PI4KA complex regulation by the phosphatase Calcineurin

Project description:To examine the interaction between PI4KIIIa and Calcineurin, HDX-MS experiments comparing calcineurin or PI4KA FAM delta C alone to the calcineurin and PI4KA FAM delta C complex were carried out.

2024-09-03 | PXD043409 | Pride

Inactivation of phosphatidylinositol 4-kinase IIIalpha (PI4KA) by GSK-A1 inhibitor in HEK293 cells

Project description:Phosphatidylinositol 4-kinases (PI4Ks) are lipid kinase enzymes that play important roles in cellular signaling, membrane trafficking, viral replication and lipid metabolism. They catalyze the phosphorylation of phosphatidylinositol (PI) to produce phosphatidylinositol 4-phosphate (PI4P) at various organelle membranes. Among the four isoforms of PI4Ks, PI4KA is localized at the plasma membrane where it generates the lipid, PI4P. GSK-A1 is a well-characterized and specific inhibitor of PI4KA. In this study, we investigated transcriptional changes that occur following prolonged (24 h) treatment with GSK-A1. This RNA-seq analysis revealed significant changes in the mRNA levels of a distinct set of proteins, including transcription factors and small GTP-binding proteins. These changes were analyzed in the context of overall lipid level alterations induced by GSK-A1 treatment, as determined by lipidomic analyses.

2025-12-04 | GSE303723 | GEO

Metagenomics Next Generation Sequencing Data

Project description:Metagenomics Next Generation Sequencing Raw sequence reads

| PRJNA749647 | ENA